Denna webbsida är endast avsedd för läkare och sjukvårdspersonal med förskrivningsrätt.

2nd Nordic CAR T Symposium

8th October 2020, 16:00–18:00

We are pleased to welcome you to the 2nd Nordic CAR T symposium. This year’s symposia will focus on the Nordic and European experience with CAR T, followed by insights on the underlying mechanism of CRS (cytokine release syndrome).

This year the meeting will be fully digital and broadcasted live via link. Online attendees will be able to ask questions via the webinar platform. Please use the link below to register or to log-on directly when meeting starts. Please note that the registration is open right up until the start of the meeting and that pre-registration is not required. However, registrants will get an automatic reminder before the event and are able to save the event to their calendar.

For more information and registration click HERE

Liknande poster

Current treatment and recent therapeutic developments in TNBC

Current treatment and recent therapeutic developments in TNBC

We are delighted to invite you to a webinar exploring the evolving treatment landscape of metastatic triple negative breast cancer (mTNBC). Dr Mark Harries, Consultant Medical Oncologist at Guy’s and St Thomas’ in London will discuss the current and evolving…

Caring for patients with metastatic TNBC: The nurse’s perspective

Caring for patients with metastatic TNBC: The nurse’s perspective

We are delighted to invite you to a webinar focusing on caring for patients with metastatic triple negative breast cancer (mTNBC) from the nurse’s perspective. Nurse Anjali Sivajothu, Lead Clinical trials Practitioner at St Bartholomew’s Hospital in London will discuss…

EMA rekommenderar godkännande för Trodelvy (sacituzumab govitecan) från Gilead för behandling av trippelnegativ bröstcancer

EMA has recommended granting a marketing authorisation in the European Union (EU) for Trodelvy (sacituzumab govitecan), a first-in-class medicine to treat adult patients with unresectable (cannot be removed by surgery) or metastatic triple-negative breast cancer who have received two or…